RECRUITING

Evaluation of the Pathobiology of CALR-mutated MPN Cells

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.

Official Title

Evaluation of the Pathobiology of CALR-mutated MPN Cells

Quick Facts

Study Start:2025-01-21
Study Completion:2026-02
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06480591

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Written (or electronic) informed consent and HIPAA authorization for release of personal health information by participant or his/her legally authorized representative (LAR).
  2. * Age ≥ 18 years at the time of enrollment
  3. * Diagnosis of myeloproliferative neoplasm (MPN) according to 2022 World Health Organization classification of MDS/MPNs
  4. * CALR-positive genetic mutation
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Courtney Schepel
CONTACT
(980) 292-0817
Courtney.Schepel@atriumhealth.org

Principal Investigator

Aleksander Chojecki, MD
PRINCIPAL_INVESTIGATOR
Atrium Health Levine Cancer

Study Locations (Sites)

Atrium Health Levine Cancer
Charlotte, North Carolina, 28204
United States
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157
United States

Collaborators and Investigators

Sponsor: Wake Forest University Health Sciences

  • Aleksander Chojecki, MD, PRINCIPAL_INVESTIGATOR, Atrium Health Levine Cancer

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-21
Study Completion Date2026-02

Study Record Updates

Study Start Date2025-01-21
Study Completion Date2026-02

Terms related to this study

Additional Relevant MeSH Terms

  • Myeloproliferative Neoplasm